Real-world external validation of the Society for Immunotherapy of Cancer (SITC) definitions of primary and secondary resistance to PD-1/PD-L1 inhibitors in patients with solid tumors

Purpose The Society for Immunotherapy of Cancer (SITC) definitions of primary and secondary resistance to PD-1/PD-L1 inhibitors are widely used but were independently evaluated mainly in melanoma. We assessed their prognostic performance in a real-world pan-tumor cohort and explored alternative cutoffs. Methods This retrospective single-center study included adults with solid tumors treated with PD-1/PD-L1 inhibitors for at least 6 weeks, classified as having primary, secondary, or no resistance per the 2020 SITC definitions. Overall survival (OS) was analyzed using Kaplan–Meier methods and multivariable Cox regression, and the threshold separating primary from secondary resistance was varied from 3 to 24 months. Results Of 595 patients (49% non-small cell lung cancer), 294 (49.4%) had primary resistance, 125 (21.0%) secondary resistance, and 176 (29.6%) no resistance. At a median follow-up of 27.7 months, median OS was 28.5 months with primary resistance, 80.3 months with secondary resistance, and not reached without resistance (log-rank p < 0.0001). In multivariable analysis (n = 398), primary resistance (adjusted hazard ratio [aHR] 6.99, 95% CI 3.58–13.6) and secondary resistance (aHR 2.15, 95% CI 1.06–4.35) were associated with higher mortality; estimates were consistent without performance status (n = 568). A 3-month threshold yielded a concordance statistic of 0.777 versus 0.769 at 6 months; longer thresholds progressively reduced discrimination. Conclusion SITC-defined resistance categories stratified OS in this real-world pan-tumor cohort. A shorter threshold did not meaningfully improve discrimination, supporting retention of the 6-month cutoff. Because categories are assigned after treatment initiation, landmark-based and prospective validation is warranted.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11555640/v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Real-world external validation of the Society for Immunotherapy of Cancer (SITC) definitions of primary and secondary resistance to PD-1/PD-L1 inhibitors in patients with solid tumors

Ali Awada, Firas Kreidieh, Lara Soueid, Heba Sati et al.
1 links
Research Square
Cancer Immunotherapy and Biomarkers
preprint

Real-world external validation of the Society for Immunotherapy of Cancer (SITC) definitions of primary and secondary resistance to PD-1/PD-L1 inhibitors in patients with solid tumors

Ali Awada, Firas Kreidieh, Lara Soueid, Heba Sati, Ali Tarhini, Ahmad Moukachar, Akel Khaled, Mohammad Kassem, Roy El Darzi, Nicole Charbel, Ali Hajj Ali, Sary Faraj, Duha Awada, Mohammad Hassan, Teia El Hajj, Mahdi Mansour
preprint en

Abstract

Purpose The Society for Immunotherapy of Cancer (SITC) definitions of primary and secondary resistance to PD-1/PD-L1 inhibitors are widely used but were independently evaluated mainly in melanoma. We assessed their prognostic performance in a real-world pan-tumor cohort and explored alternative cutoffs. Methods This retrospective single-center study included adults with solid tumors treated with PD-1/PD-L1 inhibitors for at least 6 weeks, classified as having primary, secondary, or no resistance per the 2020 SITC definitions. Overall survival (OS) was analyzed using Kaplan–Meier methods and multivariable Cox regression, and the threshold separating primary from secondary resistance was varied from 3 to 24 months. Results Of 595 patients (49% non-small cell lung cancer), 294 (49.4%) had primary resistance, 125 (21.0%) secondary resistance, and 176 (29.6%) no resistance. At a median follow-up of 27.7 months, median OS was 28.5 months with primary resistance, 80.3 months with secondary resistance, and not reached without resistance (log-rank p < 0.0001). In multivariable analysis (n = 398), primary resistance (adjusted hazard ratio [aHR] 6.99, 95% CI 3.58–13.6) and secondary resistance (aHR 2.15, 95% CI 1.06–4.35) were associated with higher mortality; estimates were consistent without performance status (n = 568). A 3-month threshold yielded a concordance statistic of 0.777 versus 0.769 at 6 months; longer thresholds progressively reduced discrimination. Conclusion SITC-defined resistance categories stratified OS in this real-world pan-tumor cohort. A shorter threshold did not meaningfully improve discrimination, supporting retention of the 6-month cutoff. Because categories are assigned after treatment initiation, landmark-based and prospective validation is warranted.

Research Square
American University of Beirut Medical Center (LB)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon